Solemn Statement

Recently, criminals have been fraudulently using our company's name to operate a "Ponzi scheme," inducing users to deposit funds through an app called "OKX" (欧易), then conducting so-called "investment activities" on a forged "Qiming Venture Partners (QMVP)" app, apparently for illegal profit.

The criminals induce users to engage in two types of "investment activities," including but not limited to: purchasing investment products or depositing funds into a "current treasure" (活期宝) account. The investment products include five categories: "Beginner Recommended," "Quality Funds," "Stable Wealth Management," "Selected Fixed Investment," and "Premium Exclusive," with terms of 4 days, 11 days, 21 days, and long-term options, each with significantly different interest rate cycles; deposits into the "current treasure" use a daily interest rate mechanism, settled on T+1 and T+2 cycles. The criminals have set absurdly high yields for these so-called "investment activities," which already constitute suspected violations of relevant laws and regulations.

Our company strongly condemns these actions: beyond infringing upon Qiming Venture Partners' registered trademark rights, commercial reputation, and other legitimate interests, the criminals' conduct has seriously disrupted our daily operations.

Our company solemnly declares: we have no legal or commercial relationship whatsoever with the above infringing activities. We have reported and filed complaints with relevant authorities, and reserve the right to pursue legal liability against the criminals.

Our company reminds you: private equity funds only raise capital from specific qualified investors who meet certain conditions. We urge all investors and entrepreneurs to remain vigilant, verify authenticity, and not trust investment products with absurdly high returns promoted through online information, WeChat groups, apps, or other channels. Please avoid accessing illegal web links and scanning QR codes from unknown sources to access or download suspicious investment information. Please download and install the National Anti-Fraud Center App through official app stores, and promptly report to public security authorities, to effectively protect your own interests and avoid financial losses.

Our company reiterates: Qiming Venture Partners has no official app, nor does it maintain customer service staff targeting retail consumers. Our official website is: https://www.qimingvc.com, official WeChat public account is: Qiming Venture Partners (ID: Qiming_Venture), contact phone numbers are: 010-59611188 (Beijing), 021-61016522 (Shanghai), 00852-36203601 (Hong Kong), and contact email is: contactus@qimingvc.com.

This solemn statement is hereby issued.

Qiming Venture Partners October 18, 2025

Past Highlights

Solemn Statement Qiming Honors | Qiming Venture Partners Ranks 5th on Zero2IPO's 2024 China VC Firms List, Wins Five Awards Qiming Headlines | Qiming Venture Partners and Portfolio Companies Win Multiple Awards on ChinaVenture's 2024 Rankings, Including Top 5 China Best VC Firms

Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.

To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. More than 80 portfolio companies have become recognized unicorns or super-unicorns.

Many of Qiming Venture Partners' portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ: WRD), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.